Tagged News
ONWARD Medical Advances Brain-Computer Interface Technology with Fifth Successful Implant for Spinal Cord Injury Patients
• ONWARD Medical has successfully implanted its ARC-BCI® Therapy in two additional patients, bringing the total to five individuals with spinal cord injuries who can now potentially control movement through thought.
• The innovative DigitalBridge™ system creates a wireless connection between brain and spinal cord, using AI to decode neural signals and translate intention into movement, bypassing damaged neural pathways.
• With FDA Breakthrough Device Designation and growing clinical evidence, ONWARD's less invasive BCI approach is positioning the company as a leader in neurotechnology for restoring function after paralysis.
Protagenic Therapeutics Secures $3.1 Million to Advance CNS Drug Pipeline Following Phytanix Bio Merger
• Protagenic Therapeutics (Nasdaq: PTIX) has raised $3.1 million through warrant exchanges and exercises, bolstering its financial position to advance peptide-based drug candidates for CNS disorders.
• The funding comes immediately after Protagenic's business combination with Phytanix Bio on May 19, 2025, creating a unified company with six complementary drug programs targeting stress disorders, epilepsy, and obesity.
• The merged entity combines Protagenic's expertise in peptide therapeutics with Phytanix's specialization in cannabinoid and cannabinoid-like molecules, potentially strengthening their competitive position in neurological drug development.
FDA Approves First Blood Test for Alzheimer's Diagnosis, Boosting Roche and BioArctic Shares
• The U.S. Food and Drug Administration has approved the first blood test for diagnosing Alzheimer's disease, potentially revolutionizing patient identification and treatment pathways.
• The diagnostic breakthrough is expected to drive market activity for pharmaceutical companies Roche and BioArctic, whose shares showed positive movement following the regulatory announcement.
• This blood test could significantly streamline the Alzheimer's diagnostic process, making it more accessible and efficient compared to traditional methods that rely on expensive brain scans and invasive procedures.
ImmuPharma Advances P140 Autoimmune Program with Novel Non-Immunosuppressive Mechanism
• ImmuPharma has made significant scientific breakthroughs with its P140 program, confirming a unique non-immunosuppressive mechanism of action for treating autoimmune conditions.
• The company plans to increase P140 dosage up to 20 times higher than previously tested, following FDA guidance and pharmacokinetic studies, potentially enhancing efficacy without steroid-like side effects.
• ImmuPharma is in active discussions with several global commercial partners while also advancing its anti-infective portfolio targeting fungal and bacterial infections.
Sleep Disturbances in ICU Patients: New Research Reveals Impact on Recovery and Outcomes
• New research presented at ATS 2025 reveals that sleep patterns in ICU patients may serve as important biomarkers for predicting patient outcomes, with atypical N3 sleep linked to longer ICU stays.
• A study of ICU patients found that hypersomnia (sleeping more than 11 hours in 24 hours) was associated with higher mortality rates, longer hospital stays, and lower rates of discharge to home.
• Over 60% of ICU survivors with acute respiratory failure experience insomnia, with pre-existing mental health conditions and neurologic causes of respiratory failure significantly increasing this risk.
SP-102 Shows Clinically Meaningful Results for Sciatica Treatment in CLEAR Trial Analysis
• Scilex Holding Company presented post-hoc analysis of the C.L.E.A.R. trial demonstrating clinically meaningful safety and efficacy of SP-102 (SEMDEXA™) for lumbosacral radicular pain at the ASIPP Annual Meeting.
• The analysis showed clear separation between SP-102 and placebo in multiple endpoints, with enhanced results in the modified intent-to-treat population that received confirmed study drug.
• SP-102's viscous gel formulation was specifically designed as a safer alternative to current off-label products that carry warnings about potentially dangerous and life-threatening adverse events.
Acadia Pharmaceuticals Wins Patent Infringement Case Against Aurobindo for Parkinson's Drug Nuplazid
• A U.S. District Court ruled that Aurobindo Pharma infringes on two key patent claims held by Acadia Pharmaceuticals for its Parkinson's disease drug Nuplazid.
• The court rejected Aurobindo's arguments that Acadia's patent claims were invalid, providing significant intellectual property protection for Acadia's flagship product.
• Following the favorable ruling, Acadia's stock soared by over 34% to a one-year high of $23.61, reflecting investor confidence in the company's market position.
Riliprubart Shows Promise in CIDP Treatment with Significant Neurofilament Light Reduction
• Phase 2 study results reveal that Sanofi's investigational riliprubart reduced plasma neurofilament light levels by 31% in patients with chronic inflammatory demyelinating polyneuropathy.
• Greater reductions in neurofilament light levels correlated with higher treatment response rates, with up to 69% of patients showing improvement in disability scores.
• Riliprubart, a selective inhibitor of the classical complement pathway, is now being evaluated in two global Phase 3 trials (MOBILIZE and VITALIZE) across 28 countries.
Related Clinical Trials:
Octapharma
Posted 9/27/2017
Novel AAV Capsid Shows Unprecedented Brain Transduction Potential for Gene Therapy
• Latus Bio has developed AAV-Ep+, a novel AAV capsid variant that demonstrates exceptional ability to transduce ependymal cells and cerebral neurons in both mice and non-human primates.
• The breakthrough capsid enables efficient protein secretion into cerebrospinal fluid, potentially allowing single-administration gene therapies for lysosomal storage disorders and other neurological diseases.
• In preclinical studies, low-dose administration of AAV-Ep+ expressing human TPP1 achieved protein levels significantly exceeding those of natural AAV capsids, reaching potentially therapeutic levels for CLN2 disease patients.
Merck KGaA Joins Peregrine Ventures' Incentive Incubator as Strategic Partner
• Merck KGaA has become a strategic partner in Peregrine Ventures' Incentive Incubator, gaining early access to startups in bioconvergence, pharma, and biotechnology fields.
• The collaboration will focus on ventures with significant market potential aligned with Merck's three global divisions: Healthcare, Life Science, and Electronics, with priority given to bioconvergence ventures.
• Through this partnership, eligible startups will receive support including investments, regulatory guidance, business development assistance, and potentially early-phase trial planning.